DEV

You are viewing our development site. Please share feedback with support@dosevault.ai or on our Discord server. See what is new in the changelog.

DHEA (Prasterone)

DHEA is synthesized primarily in the adrenal cortex from cholesterol. Peripherally, it is converted by enzymes (3-beta-HSD, 17-beta-HSD, and aromatase) into active androgens (androstenedione, testosterone) and estrogens in a tissue-specific, dose-dependent manner. This intracrinology model means that androgenic and estrogenic effects vary substantially by tissue type. DHEA also has direct neurosteroid activity, modulating GABA-A and NMDA receptor function in the CNS.

Molecular Profile
small-molecule
10 AA Sequence
Evidence grade (Moderate): Small clinical studies or well-designed non-RCT human research. This grade reflects the overall quality of available research on this compound and does not constitute a clinical recommendation.
CAS
53-43-0
Mol. weight
288.4 g/mol
Onset and duration

Injectable esters release over days to weeks depending on the ester; oral agents act within hours. Hormonal effects accrue over weeks, and dosing is individualized by a clinician.

Storage and reconstitution

Oral capsule or tablet (supplement): store at controlled room temperature in a dry place. Intrarosa vaginal insert: store at room temperature; see product labeling.

Clinical Evidence

What the literature says

Pharmacokinetics

Routes
Oral

Last reviewed: 2026-06-15

Research Guide

How users approach this compound

The following reflects patterns observed in research literature and community protocols. This is not medical advice and does not constitute a clinical recommendation.

Reported Uses

  • FDA-approved vaginal insert for moderate to severe dyspareunia (vulvovaginal atrophy) due to menopause
  • Widely used as an oral dietary supplement; evidence for systemic hormone optimization is mixed and largely from small or short-duration studies

Key Research Benefits

  • FDA-approved vaginal formulation (Intrarosa) for moderate to severe dyspareunia caused by vulvovaginal atrophy due to menopause
  • Serves as an endogenous precursor in steroidogenic pathways; tissue-specific conversion to active androgens and estrogens

Potential Side Effects

Acne and oily skin
Hirsutism or other androgenic effects (especially at supraphysiologic doses)
Adverse changes in lipid profile
Hormonal imbalance symptoms
Potential effects on hormone-sensitive tissues

Considerations and Cautions

  • Hormone-sensitive conditions (e.g., hormone receptor-positive cancers, benign prostatic hypertrophy)
  • Pregnancy or breastfeeding
  • Pre-existing androgenic conditions (acne, hirsutism, polycystic ovary syndrome)
  • Oral DHEA dietary supplements are not FDA-approved drugs; safety and efficacy data for systemic use are limited

Labs to monitor

Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.

  • Hematocrit / hemoglobin: DHEA conversion to testosterone carries erythrocytosis risk, particularly at higher doses.
  • Estradiol (E2): DHEA aromatizes to estradiol; monitoring appropriate especially in males.
  • PSA (prostate-specific antigen): Androgenic metabolites of DHEA may affect prostate; periodic monitoring appropriate.
  • Lipid panel: Androgenic conversion may adversely affect HDL.
  • Total testosterone / free testosterone: Confirms degree of androgenic conversion and avoids supratherapeutic levels.

Dose Calculator

Peptide Reconstitution Calculator

mg

Total amount of peptide in the vial.

mL

Volume of water used to mix.

mcg

Draw to this mark

10 Units

or 0.10 mL on a U-100 syringe

Concentration:2.50 mg/mL
Peptide per Unit:25.00 mcg/unit
*Always double-check your calculations. This tool is for educational purposes only.

Related Tools

Not medical advice

Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.